It has been demonstrated that fibroblast growth factor 2 (FGF2)-enriched exosomes from bone marrow stromal cells are endocytosed by leukemia cells (AML) and protect leukemia cells from tyrosine kinase inhibitors (TKIs). This evidence concerns the gene FGF2 and acute myeloid leukemia.